DrBrainRx review

DrBrainRx names its founder, Dr. Sara Siavoshi, and prices NAD⁺ at $275 per 10 mL vial with injection supplies. Active membership is required, but the NAD⁺ page does not specify its fee tier or shipping charge. The clinic describes the vial as one month and also as multiple weeks depending on prescribed use. Its lower GLP-1 headlines require prepaid bundles, with a separate $25 monthly care fee. Get the complete NAD⁺ quote and your state eligibility before paying.

DrBrainRx is a neurologist-led telehealth clinic founded by Dr. Sara Siavoshi and operated by Siavoshi Inc., a California professional corporation. It describes itself as prescribing GLP-1s, NAD⁺ and other peptide therapies online. Its main line is compounded semaglutide and tirzepatide, alongside separate brand-name tracks through insurance, Lilly Direct or TrumpRx. NAD⁺ injection is its priced wellness product; general references to personalized peptide stacking and copper peptides do not establish orderable CJC-1295/ipamorelin or GHK-Cu products. The footer links LegitScript verification; link presence does not establish current certification.

Online intake and clinician review lead to prescribing if appropriate. The homepage separates cash-pay compounded and peptide care from medication at $25 a month, and brand-name care at $99; the NAD⁺ product requires membership without identifying its tier. Membership can be canceled through the portal with access through the paid cycle. GLP-1 Care Access is the only automatic recurring charge on those product pages; medication refills are requested and paid by the patient. The GLP-1 prescribing list is California, Florida, Kentucky, Maine, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire, New York, Ohio, Rhode Island, South Carolina, Texas, Utah, Wyoming, Colorado, North Carolina, Indiana and Nebraska. Being physically in a licensed state for prescribing is separate from the stated ability to ship an issued prescription to all 50 states; NAD⁺ access is unconfirmed. Terms require US adults aged 18 or local majority. Labs are not required; recommended thyroid or metabolic panels use a local lab slip. Processing estimates differ: three to five business days on the NAD⁺ page, two to seven after approval in the shipping policy, plus carrier transit. Privacy terms describe provider, pharmacy and advertising sharing, including cross-context advertising despite a no-sale statement.

NAD⁺ is $275 per 10 mL vial, pre-reconstituted with injection supplies. Concentration, prescribed duration, membership tier, shipping and the complete first or refill charge are unconfirmed. Compounded semaglutide Monthly Flex is $199; three months is $495 upfront ($165 monthly equivalent), six months $774 upfront ($129 equivalent). Tirzepatide is $299, $807 upfront ($269 equivalent), or $1,494 upfront ($249 equivalent). Each also requires $25 monthly Care Access. Three-month supply ships together; six-month supply ships in two three-month batches with a check-in. Bundles begin at purchase and must be used within the purchased term. FAST50 applies to eligible Flex orders, not bundles. Brand-name Lilly-track figures conflict: the homepage shows $299 initially and $399–$449 later, its comparison lists $349–$499 later, and the FAQ describes $349 initially, $499 with a refill within 44 days and $650 later. Confirm that separate track directly; those figures are not verified manufacturer prices.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. DrBrainRx says its compounded medications are filled through USP-certified US pharmacies and describes its NAD⁺ as coming from a licensed 503A pharmacy, independently tested for sterility and potency. It names no individual pharmacy, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence for NAD⁺: injected NAD⁺ has no controlled human outcome trials behind the energy, focus and healthy-aging claims attached to it. The single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly. The NAD⁺ forms with human data are the oral precursors NR and NMN, which reliably raise blood NAD⁺, a biomarker rather than a demonstrated clinical outcome. On the GLP-1 side, the compounded products target the same receptors as branded semaglutide and tirzepatide but are not therapeutically equivalent to them. Individual results vary.